{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-065373","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.397945+00:00","generated_at":"2026-06-18T07:50:20.848910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prime Medicine reports FY 2022 net loss of $121.8M; nominates first development candidate PM359 for CGD","bullets":["Q4 2022 net loss $39.3M; full-year net loss $121.8M vs $165.4M in 2021.","Cash, short-term investments $293.9M as of Dec 31, 2022, sufficient into 2025.","Nominated PM359 as first development candidate for chronic granulomatous disease; IND-enabling studies planned in 2023.","Preclinical proof-of-concept data for Friedreich's ataxia, cystic fibrosis, Wilson's disease, and PASSIGE technology disclosed.","October 2022 IPO raised $180.2M net proceeds from upsized offering at $17.00 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-065373","json":"https://secwatch.observer/filing/0001193125-23-065373.json","markdown":"https://secwatch.observer/filing/0001193125-23-065373.md","text":"https://secwatch.observer/filing/0001193125-23-065373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/0001193125-23-065373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/d367061d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:50:20.848910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed63ae86966720b34e5d1d8f6f9bca2f09b689a1","claim":"Prime Medicine, Inc. reported fourth quarter and full year ended December 31, 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022.","evidence_excerpt":"Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/0001193125-23-065373-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}